Biological clocks are intrinsic time-keeping systems that regulate behavior and physiological functions in most living organisms. Previous works suggested a possible link between the endogenous circadian clock and cell cycle regulation. The mammalian Period-2 gene (mPer2), an important component of the circadian clock mechanism, is recently demonstrated to play an important role in repressing tumor growth. In this study, we found that polyethylenimine-mediated intratumoral Per2 gene delivery had significant antitumor effects in C57BL/6 mice transplanted with Lewis lung carcinoma. Our data illustrated that the Per2 gene delivery inhibited PCNA expression and induced apoptosis. Our results support the emerging role of the circadian clock in critical aspects of tumorigenesis. These findings underscore the potential use of Per2 gene delivery as a novel therapeutic intervention for the treatment of malignant tumors.
Introduction
Circadian rhythms are major characteristic of most living organisms and represent one of the most evident manifestations of adaptation to our environment. 1 So far, eight core circadian clock genes have been identified in mammals that contribute to the entrainment and pace making of the circadian rhythm. These genes include a clock gene, a gene encoding brain-muscle Arnt-like protein 1 (bmal1), three period genes (per1, per2 and per3), and two cryptochrome genes (cry1 and cry2). 2 In addition, there is evidence that the NPAS2 gene, which encodes a functional analog of the clock, may play a role in the functioning of the circadian clock in the brain as well as in peripheral organs. 3 It is now well known that mammalian tumors, even at advanced stages, are not temporally disorganized masses. The proliferation of tumor cells can be stably entrained to the host circadian rhythm or follow a tumor-specific rhythm in vivo. 4, 5 Interestingly, the disruption of circadian rhythm in SCN-lesioned mice is related to an accelerated growth of implanted malignant tumors, suggesting that the circadian clock of the host might play an important role in the regulation of tumor progression. 6 Fu et al. 7 first demonstrated that Per2 may function as a potential tumor suppressor gene. When mammalian Period-2 gene (mPer2) is deleted, the suppression may be released resulting in accelerated cancer growth. 7 In previous studies, we found that overexpression of mPer2 could inhibit cell growth and induce apoptosis in cancer cells in vitro, including Lewis lung carcinoma cell (LLC) and mouse mammary carcinoma cell (EMT6). 8 We undertook the present studies to evaluate if delivery of a clock gene Per2 into growing Lewis lung tumors in C57BL/6 mice could diminish tumor growth in vivo.
Materials and methods

Mice, cell line and plasmids
The murine LLC cell line was routinely cultured as monolayers in tissue culture flasks containing Dulbecco's modified Eagle's medium (DMEM; Hyclone, Logan, Utah) supplemented with antibiotics (BioWhitaker, Walkersville, MD) and 10% fetal calf serum (FCS; Hyclone, Logan, Utah) in an atmosphere of humidified 95% air and 5% CO2 at 371C. The mammalian Per2-expression plasmid (pcDNA3.1-Per2) was a gift from Professor Steven Reppert (University of Massachusetts Medical School, USA).
Studies performed with animal models were approved by the Ethics Committee of the Sichuan University and were performed according to the prescribed guidelines. Male or female (50:50) C57BL/6 mice at the age of 4 weeks were housed under a standardized 12h: 12 h light/ dark cycle at room temperature of 24711C and a humidity of 60710% with food and water ad libitum.
The animals were adapted to the 12h:12 h light/dark cycle for 2 weeks before the experiments. Under the 12h:12 h light/dark cycle, times was referred to light onset (hours after light onset ), so-called Zeitgeber time (ZT). ZT 0 was designated as lights on and ZT 12 as lights off.
Tumor induction and measurement
Tumors were induced by the subcutaneous injection of 1.5 Â 10 6 LLC cells into the right supra scapular area of each mouse. Fourteen days after inoculation, the animals were randomly divided into three groups. pcDNA3.1-Per2 group, ten mice; pcDNA3.1 group, ten mice; PBS group, eight mice. Tumor volumes were determined before and at regular interval following treatment. Tumors were measured every three days after first injection (14 days after inoculation) by technician who was blind to the treatment. Two bisecting diameters of each tumor were measured with calipers. The tumor volume was estimated according to the following formula: tumor volume (mm 
Intratumoral plasmid treatment
Linear polyethylenimine (PEI) 9 was used to achieve efficient in vivo gene transfer into tumor cells. The tumor-bearing mice of Per2 group were injected intratumorally with DNA/L-PEI complexes of pcDNA3.1-Per2 and in vivojetPEIt; pcDNA3.1 group with complexes of pcDNA3.1 and in vivo-jetPEIt; and PBS group with complexes of PBS and in vivo-jetPEIt according to the instructions of the manufacturer. The injection was performed at ZT 14 every three days. The first injection was performed 14 days after inoculation and the last injection was performed 29 days after inoculation (five times for 15 days).
Immunohistochemical analysis
Mice were sacrificed and subcutaneous tumors were isolated two days after the last (fifth) injection at ZT 6. Body weights were measured. Tumors were dissected around its margin. Tumor weights and tumor diameters were subsequently determined. All these procedures were done by technician who was blind to the treatment. The tumor samples were fixed in 10% formalin solution, dehydrated and embedded in paraffin. Thin-sliced sections were prepared and stained with hematoxylin and eosin. The sections were used for immunohistochemical staining to detect PER2 and PCNA expression in the tumor. The sections were fixed in ethanol, quenched with 0.3% hydrogen peroxide, blocked in 5% rabbit serum for 30 min at room temperature and endogenous avidin and biotin blocked using a blocking kit. The sections were treated with primary antibody (1:20) at room temperature for 1 h. Secondary antibody and biotinylated antibody, (1:1000) were added at room temperature for 45 min. The primary-secondary antibody complexes were detected using the Vector Elite ABC standard HRP kit according to the manufacturer's instructions, with DAB as substrate. The immunoreactivity was analyzed through image pro plus software (Media CY Company). The PER2 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
RT-PCR
Total RNA was isolated with Trizol reagent (InvitrogenLife Technologies, Basel, Switzerland) and converted to a single-stranded cDNA by reverse transcriptase with oligo(dT) primer. Synthesized cDNA was used as a template in PCR. The mouse Per2 primers are: forward, 5 0 -GCAACGAGCCCTCAGACA-3 0 and reverse, 5 0 -GGACCCACGGATGAACCT-3 0 , which amplifies a 495 bp fragment (Genbank Acession no. NM_011066). GAPDH primers were used as an internal control. 
Flow cytometry
Statistic analysis
The results were expressed as means7s.d. or means7s.e. as indicated. The difference was considered statistically significant when the P-value was less than 0.05. Student's t-test was used for comparison among different groups. The analysis of variance for repeated measures was used for the statistical analysis of tumor volume over time.
Results and discussion
To evaluate the effects of Per2 gene delivery on tumor growth of C57BL/6 mice, the tumor-bearing mice of Per2 group (10 mice) were injected intratumorally with DNA/ L-PEI complexes of pcDNA3.1-Per2 and in vivo-jetPEIt. Complexes of pcDNA3.1 and in vivo-jetPEIt, or complexes of PBS and jetPEIt were injected into tumors of pcDNA3.1 group (ten mice) or PBS group (eight mices), respectively. To confirm the comparability of the three groups with regard to tumor size at baseline, tumor volume before first intratumoral gene delivery was measured and compared statistically. There was no significant difference in tumor size among the three groups (PBS group, 98.75713.02 mm Figure 1d ). Per2 overexpression in tumors also led to a significant decrease in tumor volume and growth rate (Po0.01; Figure 1e ). Photographs of tumors are presented in Figure 1f . In the present study, no death of animal or changes of behavior were observed. There was no significant difference in body weight among the three groups at the end point (PBS group, 20.4072.52 g; pcDNA3.1 group, 20.1973.83 g; Per2 group, 18.0772.72 g, P40.05).
To investigate whether Per2 delivery has effect on tumor cell proliferation, we evaluated the percentage of proliferating cells in all tumors by immunohistochemical staining for PCNA. Per2-treated tumors were demonstrated to have significantly lower percentages of proliferating (PCNA-positive) tumor cells than that in the pcDNA3.1 group or PBS group (Po0.01; Figure 1g ). To evaluate the effect of Per2 delivery on apoptosis of tumor cell, cell cycle and apoptotic damage of DNA in empty vector and Per2 group were determined by a flow cytometer. After quantification, we observed low-level apoptosis in tumors of the pcDNA3.1 group. In contrast, Per2 overexpression resulted in significant induction of apoptosis in tumors of the pcDNA3.1-Per2 group (Figures 1h and i; Po0.01) .
In summary, this study establishes the basis for the PEI-mediated, intratumoral Per2 gene delivery as a potential therapeutic intervention in tumor development. The overexpression of Per2 had a significant effect on the growth of LLC cells both in vitro and in vivo. An antiproliferative effect following transfection of pcDNA3.1-Per2 was also observed in other cultured tumor cells as well. 8, 10 In this study we show that the reduced tumor cell proliferation following PEI-mediated intratumoral Per2 gene delivery was due to apoptosis. Per2 gene overexpression altered some of the key factors involved in cell cycle and apoptosis directly or indirectly. 8 Recently it was reported that NK/NKT cell function and immune host response were impaired in Per2-deficient mice. This has been attributed to decreased interferon-g (IFN-g) production in Per2 À/À mice. Since both NK cells and IFN-g have been shown to be critical effectors for host immune response against tumor progression, intratumoral Per2 delivery may inhibit tumor growth by boosting the immune response executed by infiltrating NK/NKT cells. 11 Taken together, our results help define how the circadian clock functions in the peripheral tissues to control the cell cycle, apoptosis and malignant growth. Genetic and molecular data show that the circadian system regulates multiple stages of the cell-cycle pathway. 12 Our previous finding that Per2 overexpression results in a significant G1/S arrest is in agreement with several earlier studies showing that the G1/S checkpoint was under circadian control. 8 In addition to p53-dependent apoptosis, there may be other mechanisms by which overexpressed Per2 induces apoptosis. Thus, the results of our studies suggest that targeted regulation of Per2 gene expression could lead to the development of a novel therapeutic intervention for cancer treatment.
Abbreviations mPer2, mammalian Period 2; LLC, Lewis lung carcinoma.
